# Vaccinex (VCNX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/VCNX
## Company Profile
- Ticker: VCNX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Immunology
## Stock Data
- Close: 1.06 USD
- Market cap: Not available USD
- Last updated: 2026-09-08
## Business Overview
Vaccinex is a biotechnology company focused on antibody therapies and immunology, with a history of pursuing difficult oncology and neurodegenerative targets. Its story is tied to platform science and the challenge of turning it into durable value.
## Why The Stock Is Moving

Current closing-price context is not available for VCNX.

## Geographic Base

Vaccinex is headquartered in the United States and listed on NASDAQ. It sits in small-cap biotechnology with a therapeutic platform focus.

## Business Model

The business model depends on clinical validation, strategic partnerships, and capital management. Investors typically track early data, platform breadth, and whether the company can progress a narrow pipeline without dilution pressure.

## Landscape Position

Vaccinex sits in a high-risk platform-biotech niche. It remains catalyst-sensitive because the company's value depends on a limited number of programs and the market's belief in its science.

## Future Catalysts

- Vaccinex is still a broad antibody-platform story, with Alzheimer’s, Huntington’s disease, and cancer all sitting inside the same frame. That breadth is useful, but the company now needs one of those programs to move from scientific promise to something more concrete.

## Recent News
- 2026-04-30 00:05 EST — [Vaccinex Reports 2025 Annual Financial Results](https://biopharmsignal.com/news/VCNX/vaccinex-reports-2025-annual-financial-results) — Source: Vaccinex
- 2025-12-23 13:01 EST — [Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease](https://biopharmsignal.com/news/VCNX/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease) — Source: Vaccinex
- 2025-05-27 12:45 EST — [Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting](https://biopharmsignal.com/news/VCNX/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting) — Source: Vaccinex
- 2025-04-21 12:45 EST — [Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)](https://biopharmsignal.com/news/VCNX/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemab-s-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr) — Source: Vaccinex
- 2025-03-07 22:15 EST — [Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market](https://biopharmsignal.com/news/VCNX/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market) — Source: Vaccinex